• Aptamer-based COVID-19 diagnostics

COVID-19 Reagents

COVID-19 Reagents We invite development partners to join us in this endeavour

Applications of aptamers in detection and therapeutics of SARS-CoV

The world is currently gripped by the novel COVID-19 crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a highly pathogenic viral respiratory illness. It is an enveloped positive sense single stranded RNA virus that enters its host by binding to the ACE2 receptor (Figure 1). Two strains of the virus have […]

Aptamers enhance targeted delivery of CRISPR/Cas9 in tumour tissues in vivo

Osteosarcoma (OS) is a highly aggressive pediatric cancer, characterized by frequent lung metastasis and pathologic bone destruction. Vascular endothelial growth factor A (VEGFA) that is highly expressed in OS contributes to angiogenesis within the tumour microenvironment. However, it also acts as an autocrine survival factor for tumour cell themselves, making it a promising therapeutic target […]

Optimizing your PCR to avoid non-specific amplification – Aptamer mediated Hot start PCR to detect MERS-CoV

Polymerase chain reaction (PCR) is an established method to amplify specific fragments of DNA, for applications such as gene cloning, genetic fingerprinting and diagnosis of disease. Although PCR reactions have historically been set up at room temperature, this approach is highly susceptible to non-specific amplification. Such non-specific amplification often complicates data analysis and can even […]

Aptamers help to facilitate specific protein purification

Purification of functional proteins is a key procedure in the development and production of biologics and relies on traditional ion exchange (IEX), hydrophobic interaction (HIC) or size exclusion chromatography (SEC). Although these techniques are relatively gentle, obtaining the desired level of purity requires many sequential and repeated purification steps. Affinity separation is also a frequently […]

Aptamers in therapeutic drug monitoring for Cystic Fibrosis

Cystic fibrosis (CF) is one of the most lethal autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). It is estimated that about 60–70% of CF patients develop Pseudomonas aeruginosa chronic infection, with progressive loss of lung function, as well as increased antibiotic resistance and mortality.

Tobramycin has become an important […]

Aptamers in prostate cancer in vivo research

Prostate cancer is the most common cancer among men, with approximately 1.1 million new cases diagnosed per year worldwide. Most cancer-related deaths are caused by metastases in vital organs, with bones among the most frequent sites of prostate cancer metastases.

So far, various synthetic carriers have been developed to form compact nano-sized complexes carrying cancer therapeutics […]

Aptamers help to combat HIV

Human immunodeficiency virus (HIV) is the primary cause of acquired immune deficiency syndrome (AIDS)

Aptamer Group and Valitacell announce partnership to build new drug discovery platform

Biotechnology companies Aptamer Group and Valitacell Ltd have joined forces to develop a next-generation screening platform for drug development.
Aptamer Group will be working alongside Valitacell to engineer the platform, in which aptamers – short sequences of DNA or RNA – are used in Valitacell’s high throughput screening processes. These screening processes can rapidly identify promising […]

Aptamers enhance targeted gene therapy using viral vectors

Virus mediated gene therapy has emerged as a powerful and promising option for the treatment of various diseases such as metabolic, cardiovascular, muscular, hematologic, ophthalmologic, and infectious diseases and different types of cancer.

Among the viral vectors, adeno-associated virus (AAV) is particularly attractive because of its properties of low immunogenicity, high transfection efficiency and long-term transgene […]